Insys Therapeutics, Inc.
INSY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INSY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2019.
Tracking 3 pipeline candidates for Insys Therapeutics, Inc..
Run Insys Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Insys Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
15.9 months
OCF -$17M · Net income -$124M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is Insys Therapeutics, Inc.'s lead drug candidate?
Insys Therapeutics, Inc.'s most advanced tracked candidate is naloxone (Preclinical) for Opioid antagonist.
What therapeutic areas does Insys Therapeutics, Inc. focus on?
Insys Therapeutics, Inc. develops therapies across Oncology, Pain, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.